Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
N Engl J Med
    October 2025
  1. SHORE ND, Luz MA, De Giorgi U, Gleave M, et al
    Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.
    N Engl J Med. 2025 Oct 19. doi: 10.1056/NEJMoa2510310.
    >> Share

    August 2025
  2. BANCROFT EK, McHugh JK, Eeles RA
    Screening for Prostate Cancer with a Polygenic Risk Score. Reply.
    N Engl J Med. 2025;393:832.
    >> Share

  3. GREEN HD, Jackson L, Bailey SER
    Screening for Prostate Cancer with a Polygenic Risk Score.
    N Engl J Med. 2025;393:831-832.
    >> Share

  4. SU CY, Hasebe M
    Screening for Prostate Cancer with a Polygenic Risk Score.
    N Engl J Med. 2025;393:831.
    >> Share

  5. EKLUND M, Thompson IM Jr, Cooperberg MR
    Screening for Prostate Cancer with a Polygenic Risk Score.
    N Engl J Med. 2025;393:831.
    >> Share


  6. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
    N Engl J Med. 2025 Aug 1. doi: 10.1056/NEJMx250003.
    >> Share

    April 2025
  7. MCHUGH JK, Bancroft EK, Saunders E, Brook MN, et al
    Assessment of a Polygenic Risk Score in Screening for Prostate Cancer.
    N Engl J Med. 2025;392:1406-1417.
    >> Share

    January 2025
  8. VAN AS N, Patel J, Hall E
    Stereotactic Body Radiotherapy in Localized Prostate Cancer. Reply.
    N Engl J Med. 2025;392:206-207.
    >> Share

  9. KASHIHARA T
    Stereotactic Body Radiotherapy in Localized Prostate Cancer.
    N Engl J Med. 2025;392:206.
    >> Share

    December 2024
  10. HUGOSSON J, Godtman RA, Stranne J
    Four Years of Screening for Prostate Cancer with PSA and MRI. Reply.
    N Engl J Med. 2024;391:2274.
    >> Share

  11. TILKI D, Chen MH, D'Amico AV
    Four Years of Screening for Prostate Cancer with PSA and MRI.
    N Engl J Med. 2024;391:2273-2274.
    >> Share

    October 2024
  12. VAN AS N, Griffin C, Tree A, Patel J, et al
    Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.
    N Engl J Med. 2024;391:1413-1425.
    >> Share

  13. HOLMBERG L, Garmo H, Andersson SO, Andren O, et al
    Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer.
    N Engl J Med. 2024;391:1362-1364.
    >> Share

    September 2024
  14. PINSKY PF
    Prostate Biopsy in Men with an Elevated PSA Level - Reducing Overdiagnosis.
    N Engl J Med. 2024;391:1153-1154.
    >> Share

  15. HUGOSSON J, Godtman RA, Wallstrom J, Axcrona U, et al
    Results after Four Years of Screening for Prostate Cancer with PSA and MRI.
    N Engl J Med. 2024;391:1083-1095.
    >> Share

  16. GANGULI I
    How Does Health Care Burden Patients? Let Me Count the Days.
    N Engl J Med. 2024;391:880-883.
    >> Share

    August 2024
  17. ARENAS-GALLO C, Michie M, Jones N, Pronovost PJ, et al
    Race-Based Screening under the Public Health Ethics Microscope - The Case of Prostate Cancer.
    N Engl J Med. 2024;391:468-474.
    >> Share

    January 2024
  18. SHORE ND, Tarazi J, Freedland SJ
    Enzalutamide in Biochemically Recurrent Prostate Cancer. Reply.
    N Engl J Med. 2024;390:90-91.
    >> Share

  19. POLLAK M
    Enzalutamide in Biochemically Recurrent Prostate Cancer.
    N Engl J Med. 2024;390:90.
    >> Share

    October 2023
  20. APARICIO A
    Biochemical Recurrence in Prostate Cancer - Tilting the Scale.
    N Engl J Med. 2023;389:1522-1523.
    >> Share

  21. FREEDLAND SJ, de Almeida Luz M, De Giorgi U, Gleave M, et al
    Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
    N Engl J Med. 2023;389:1453-1465.
    >> Share

  22. NADAMUNI M, D'Amico AV, Donovan JL, Hamdy FC, et al
    Decision Making in Prostate Cancer.
    N Engl J Med. 2023;389:1335-1338.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016